Home/Pipeline/NUV-868

NUV-868

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Nuvation Bio

About Nuvation Bio

Nuvation Bio is a mission-driven oncology company focused on developing next-generation therapies for cancers with high unmet need, aiming to improve efficacy and reduce side effects. A key inflection point was achieved in 2025 as the company transitioned to commercial-stage status, celebrating at the NYSE. Its strategy leverages founder David Hung's proven track record, a hybrid pipeline built on proprietary discovery and strategic acquisitions, and a global operational footprint. The company is now positioned to build a sustainable oncology franchise.

View full company profile

Therapeutic Areas

Oncology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active